STAGE II BREAST CANCER

This study looks at whether aerobic exercise can lower ctDNA levels in the blood, which may help prevent cancer from returning. About 33 people who have been treated for high-risk breast, prostate, or colorectal cancer will try different amounts of weekly exercise to find the saf…

This study tests whether a newer drug, margetuximab, works better than the standard trastuzumab when combined with chemotherapy and pertuzumab before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two combinations. The main go…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can boost the body's immune attack on HER2-negative breast cancer. About 46 adults with locally advanced disease will receive this short course, then proceed to usu…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether a shorter course of radiation (hypofractionated) after mastectomy works as well as standard radiation to prevent breast cancer from coming back. About 900 people with stage II to IIIA breast cancer took part. The shorter schedule aims to cause fewer side …

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA or PALB2 gene mutations and early-stage breast cancer. The goal is to see if the treatment shrinks tumors and boosts immune activity. 62 participants are enrolled, and the study is act…

This study tests two targeted drugs, T-DM1 and pertuzumab, given before surgery to people with early-stage HER2-positive breast cancer. The goal is to see if this combination can completely eliminate cancer cells in the breast, potentially reducing the need for more aggressive tr…

This phase 3 study tests whether a combination of two hormone-blocking drugs (fulvestrant and anastrozole) works better than anastrozole alone to shrink estrogen receptor-positive breast cancer before surgery. About 1,473 postmenopausal women with stage II or III breast cancer wi…

This study explores whether acupuncture can improve memory, focus, and thinking problems that some people experience after cancer treatment. It includes 48 adults who have finished initial treatment for breast, colorectal, prostate, or gynecologic cancer and report moderate to se…